Date | Market Capitalization | Share Price | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) |
---|
CEO | Dr. Gopal Munjal M.D. |
IPO Date | Oct. 18, 2004 |
Location | India |
Headquarters | 781, Industrial Area |
Employees | 1,054 |
Sector | Health Care |
Industries |
Ind-Swift Limited manufactures and sells pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. It offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names; gynecology, pediatrics, dermatology, and GP under the Anin, Suprox, Cozy, Distone, and Oliade name; and antibiotic, anti-cold, nutraceuticals, anti-diarrheal, anti-malarial, anti-depressants, cardiology, diabetology, neurology, and oncology. The company also provides contract research and manufacturing services. It serves government dispensaries, doctors, and hospitals through retailers, stockists, and carrying and forwarding channels. The company exports its products to approximately 50 countries. Ind-Swift Limited was founded in 1983 and is based in Chandigarh, India.
Past 5 years
USD 0.50
USD 0.22
USD 1.16
USD 2.49
USD 0.45
StockViz Staff
January 15, 2025
Any question? Send us an email